Patient
Guardant Helath is offering a range of liquid tests for
patients with early-stage and advanced-stage cancer. The
results of each test enable your doctor to:
Guideline-recommended* testing of 74 genes at diagnosis & progression.
5 days†
Guideline-complete** testing of 740+ genes at diagnosis & progression.
7 days†
Residual disease and
recurrence monitoring
Stage II or III colorectal,
breast, and lung cancer
7 days†
Important Note: Guardant Reveal™ and Guardant360® Liquid were developed as a Laboratory Developed Test (LDT), and its performance characteristics determined, by the Guardant Health Clinical Laboratory in Redwood City, CA, USA, which is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) as qualified to perform high-complexity clinical testing. This test has not been cleared or approved by the US FDA. Guardant Hereditary Cancer was developed as an LDT and is not cleared or approved by the US FDA.
†Median turnaround time from sample receipt to results.
References: 1. Guardant Health data on file. December 12, 2025. Guardant Health, Inc. Redwood City, CA., 2. Parikh AR, Van Seventer EE, Siravegna G, et al. Minimal residual disease detection using a plasma-only circulating tumor DNA assay in patients with colorectal cancer. Clin Cancer Res. 2021;27(20):5586-5594. doi:10.1158/1078-0432.CCR-21-0410., 3. Guardant360® CDx Technical Information. Guardant Health, Inc. Redwood City, CA. February 2023., 4. Guardant360® Liquid Assay Specifications. Guardant Health, Inc. Redwood City, CA. October 14, 2024., 5. Zhang Q, Luo J, Wu S, et al. Prognostic and predictive impact of circulating tumor DNA in patients with advanced cancers treated with immune checkpoint blockade. Cancer Discov. 2020;10(12):1842-1853. doi:10.1158/2159-8290.CD-20-0047.
